Literature DB >> 10772425

Effect of aging on the incidence of digoxin toxicity.

T Miura1, R Kojima, Y Sugiura, M Mizutani, F Takatsu, Y Suzuki.   

Abstract

OBJECTIVE: To evaluate the relationship of the therapeutic serum digoxin concentration (SDC) range (0.5-2 ng/mL, as recommended in previous clinical studies) with the incidence of digoxin toxicity during digoxin maintenance therapy.
METHODS: Subjects included all inpatients (n = 462) and outpatients (n = 437) receiving digoxin oral maintenance therapy for heart failure and/or atrial fibrillation with tachycardia at Kosei Hospital, Anjo, Japan. SDC and blood chemistry analysis were determined, and a 24-hour Holter electrocardiographic recording was performed when the SDC was at the presumed steady-state concentration.
RESULTS: Analysis of clinical data showed that there was an overlapping (toxic and nontoxic) range of SDCs in which the incidence of digoxin toxicity was patient-dependent (1.4-2.9 ng/mL). No patient exhibited signs or symptoms of digoxin toxicity when the SDC was <1.4 ng/mL; all patients had evidence of toxicity when the SDC was >3 ng/mL. Additionally, it was shown that the concentration range of this overlapping range tended to broaden and shift to lower concentrations with increasing age. Patients with signs of toxicity when their SDCs were in the overlapping range had normal serum creatinine, blood urea nitrogen, digoxin clearance, creatinine clearance, and potassium concentrations, except for a significantly higher mean age than patients without toxicity. The incidence of digoxin toxicity was dependent on increasing age in patients whose SDCs were within the recommended therapeutic range. Moreover, clinical evidence of digoxin toxicity in patients >71 years old was 26.5%, despite their SDCs falling between 1.4 and 2 ng/mL.
CONCLUSIONS: Increased age is most likely associated with enhanced susceptibility to digoxin toxicity, possibly due to unknown pharmacodynamic changes. This raises the possibility that patients >71 years show clinical evidence of digoxin toxicity despite having SDCs within the recommended therapeutic range.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10772425     DOI: 10.1345/aph.19103

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  12 in total

Review 1.  The influence of cardiovascular physiology on dose/pharmacokinetic and pharmacokinetic/pharmacodynamic relationships.

Authors:  Pietro Fagiolino; Rosa Eiraldi; Marta Vázquez
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

2.  Necessary cautions when considering digoxin in heart failure.

Authors:  George A Heckman; Robert S McKelvie
Journal:  CMAJ       Date:  2007-02-27       Impact factor: 8.262

3.  Population pharmacokinetics of digoxin in elderly patients.

Authors:  Rong Chen; Su-lan Zou; Ming-li Wang; Yan Jiang; Hui Xue; Chun-yan Qian; Zong-ling Xia
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2012-10-25       Impact factor: 2.441

4.  A pharmacokinetic interaction study of ticagrelor and digoxin in healthy volunteers.

Authors:  Renli Teng; Kathleen Butler
Journal:  Eur J Clin Pharmacol       Date:  2013-06-09       Impact factor: 2.953

5.  Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management.

Authors:  J Malcolm O Arnold; Peter Liu; Catherine Demers; Paul Dorian; Nadia Giannetti; Haissam Haddad; George A Heckman; Jonathan G Howlett; Andrew Ignaszewski; David E Johnstone; Philip Jong; Robert S McKelvie; Gordon W Moe; John D Parker; Vivek Rao; Heather J Ross; Errol J Sequeira; Anna M Svendsen; Koon Teo; Ross T Tsuyuki; Michel White
Journal:  Can J Cardiol       Date:  2006-01       Impact factor: 5.223

6.  Is inappropriate medication use a major cause of adverse drug reactions in the elderly?

Authors:  Marie-Laure Laroche; Jean-Pierre Charmes; Yves Nouaille; Nicolas Picard; Louis Merle
Journal:  Br J Clin Pharmacol       Date:  2006-12-07       Impact factor: 4.335

7.  Emergency department visits and hospitalizations for digoxin toxicity: United States, 2005 to 2010.

Authors:  Isaac See; Nadine Shehab; Scott R Kegler; S Raja Laskar; Daniel S Budnitz
Journal:  Circ Heart Fail       Date:  2013-12-03       Impact factor: 8.790

8.  Age-related differences in the prevalence of potential drug-drug interactions in ambulatory dyslipidaemic patients treated with statins.

Authors:  Sabin S Egger; Alexandra E Rätz Bravo; Lorenzo Hess; Raymond G Schlienger; Stephan Krähenbühl
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

9.  Cognitive toxicity of drugs used in the elderly.

Authors:  L L von Moltke; D J Greenblatt; M K Romach; E M Sellers
Journal:  Dialogues Clin Neurosci       Date:  2001-09       Impact factor: 5.986

10.  Retrospective evaluation of patients with elevated digoxin levels at an emergency department.

Authors:  Gulsum Limon; Gurkan Ersoy; Nese Colak Oray; Basak Bayram; Onder Limon
Journal:  Turk J Emerg Med       Date:  2016-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.